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ABSTRACT
Orloff, M. J., Orloff, M. S., Orloff, S. L. and Girard B.
(1997) Experimental, clinical and metabolic results of side-
to-side portacaval shunt for intractable cirrhotic ascites.
The American College of Surgeons; 184, 557-570.
Background: Intractable ascites, refractory to medi-
cal therapy, occurs in approximately 10 percent of
patients with ascites from cirrhosis and is almost
always fatal. Sinusoidal hypertension resulting from
hepatic venous outflow obstruction plays a primary
role in the pathogenesis of cirrhotic ascites and
provides the rationale for decompression of the liver
by side-to-side portacaval shunt in treatment of
intractable ascites. This report presents the experi-
mental basis for the use of side-to-side shunt and
long-term results of a prospective study in 34
selected patients with intractable cirrhotic ascites.
Study Design: In the experimental studies, hepatic
venous outflow obstruction and massive ascites
were produced in dogs by ligation of the hepatic
veins, and the effect of portacaval shunts on ascites,
thoracic duct lymph flow, and aldosterone secretion
were measured. In the clinical study, 34 carefully
selected patients with cirrhosis (91 percent alcoholic)
and truly intractable ascites (failure of medical
therapy for 5 to 24 months) underwent side-to-side
portacaval shunt. The effects on ascites, survival,
metabolic abnormalities, and quality of life were
studied prospectively during follow-up that was
longer than 5 years in all but two patients. Quan-
titative Child’s risk classes in percent of patients
were A in 0, B in 68 and C in 32.
Results: In the experimental studies, side-to-side
portacaval shunt permanently relieved severe as-
cites, reduced the 13-fold increase in thoracic duct
lymph flow rate to almost normal,and abolished the
aldosterone hypersecretory response to minimal
hepatic venous outflow obstruction. End-to-side
portacaval shunt was much less effective. In the
clinical study, side-to-side portacaval shunt reduced
mean portal vein-inferior vena cava pressure gradi-
ent from 282mm saline to 4mm and permanently
relieved all patients of ascites without subsequent
requirement of diuretic therapy. Two patients who
died of hepatoma, and one who died of heart failure
developed terminal ascites. Thirty-day mortality rate
was 6 percent and long-term survival rates at 5, 10
and 15 years were 75 percent, 74 percent and 73
percent. In metabolic studies, side-to-side shunt pro-
duced marked diuresis and natriuresis and abol-
ished hypersecretion of aldosterone. Quality of life
was generally improved as a result of a low inci-
dence of recurrent portal-systemic encephalopathy
(6 percent), abstinence from alcohol in 91 percent,
improvement in liver function in 81 percent, and
improvement in Child’s risk class. The portacaval
anastomosis remained permanently patent in every
patient.
Conclusions: Side-to-side portacaval shunt is very
effective treatment of intractable ascites from cir-
rhosis. Our results are attributable to careful selec-
tion of patients, an organized system of care, and a
program of rigorous, lifelong follow-up that empha-
sizes abstinence from alcohol and dietary protein
restriction. (J. Am. Coll. Surg., 1997; 184 557-570).
Keywords: Portacaval shunt, side-to-side shunt, ascites, re-
fractory ascites
PAPER DISCUSSION
The development of refractory ascites in cirrho-
tic patients is relatively low. It is accepted that
approximately 10 percent of the patients with
ascites either do not respond to diuretic therapy
or develop diuretic-induced complications thatHPB INTERNATIONAL 201
prevent the use of high doses of these drugs [1].
This condition is known as refractory ascites. Up
to now the definition and diagnostic criteria of
refractory ascites has not been well established.
However, recently, in the biennial Meeting of the
International Ascites Club held in Chicago in
November 1994 [2], a group of experts defined
this clinical condition. In this consensus con-
ference it was considered that refractory ascites
may be a consequence of diuretic-resistant or
diuretic-intractable ascites. Diuretic resistant
ascites was defined as ascites that cannot be
mobilized or the early recurrence of which
cannot be prevented due to a lack of response
to sodium restriction (50mEq/day sodium diet)
and diuretic treatment (mean weight loss less
than 200g/day during the last four days of
intensive diuretic therapy spironolactone
400mg/day and furosemide 160 mg/day- and
urinary sodium excretion less than 50mEq/
day). Diuretic intractable ascites was defined as
ascites that cannot be mobilized or the early
recurrence of which cannot be prevented due to
the development of diuretic-induced complica-
tions (hepatic encephalopathy, diuretic-induced
renal failure, hyponatremia, and/or hypo or
hyperkalemia), that preclude the use of an eff-
ective diuretic dosage. Moreover, most cirrhotics
with refractory ascites have moderate renal
failure or even steady hepatorenal syndrome
(HRS). Although, it is possible that refractory
ascites may be present in patients without renal
failure, this situation is very uncommon.
The treatment of refractory ascites is still
under discussion [2]. It is obvious that to
establish therapy in any clinical condition a
rationale is required. In cirrhotic patients with
ascites this should be based on the pathophy-
siology of ascites formation and HRS. At
present, it is considered that most of the
available data regarding the development of
renal functional abnormalities and ascites and
edema formation in cirrhosis are related to the
presence of an intense arteriolar vasodilattation
(Arterial vasodilatation hypothesis) [3]. This
hypothesis is based on the fact that arterial
hypotension is frequent a finding in cirrhotics
with ascites, despite an increased plasma
volume and cardiac index, and a stimulated
renin-angiotensin-aldosterone system (RAAS),
sympathetic nervous system (SNS) and anti-
diuretic hormone (ADH) that are all powerful
vasoconstrictors. In addition, the blockade of the
vascular effect of angiotensin II and ADH in
cirrhosis with ascites is associated with a
marked fall in peripheral vascular resistance
and arterial pressure, an effect not observed in
normal subjects. Therefore, by considering all
these data, it could be suggested that the initial
event in ascites formation is sinusoidal portal
hypertension leading to marked arterial vasodi-
latation located mainly in the splanchnic circula-
tion. Potential substances involved in this
vasodilatation include nitric oxide and vasodi-
lator peptides. Arterial vasodilatation leads to an
abnormal distribution of blood volume with
reduction of effective arterial blood volume and
subsequent renal sodium and water retention
due to the activation of vasoconstrictor systems.
In the preascitic stage the retained fluid volume
would suppress sodium and water retention and
reestablish fluid balance at an upper level of
blood volume. However, as the disease pro-
gresses, more vasodilatation occurs in the
splanchnic circulation and the effective arterial
blood volume can no longer be maintained by
the increased blood volume, probably because
fluid starts leaking from the splanchnic circula-
tion to the peritoneal cavity as ascites. Then, a
persistent activation of vasconstrictors and anti-
natriuretic systems occurs in an attempt to
maintain a normal effective blood volume and
arterial pressure. The continuous leakage of
intravenous fluid to the peritoneal cavity may
explain the paradox of unrelenting activation of
RAAS, SNS and ADH in the setting of an
increased extracellular fluid volume. In very
advanced stages of the disease, the disturbances
in the splanchnic circulation are so marked that
the systemic hemodynamics can be maintained202 HPB INTERNATIONAL
only at the expense of vasoconstriction in most
vascular beds, including the renal circulation,
and therefore HRS develops.
At present, there is no real effective therapy
for patients with refractory ascites. During the
last two decades several therapeutic measures
have been applied, and the rationale of the
therapy is to reduce portal pressure, to increase
the effective arterial blood volume or to improve
renal perfusion.
Portacaval anastomosis, either side-to-side or
end-to-side, was used in the past in the manage-
ment of patients with refractory ascites. How-
ever, although this technique is very useful in
controlling ascites, it has an associated high
incidence of hepatic encephalopathy [4-6].
More recently Franco et al. [7] reported the
results of portacaval shunt (most with side-to-
side type) in 57 cirrhotics (90 percent alcoholics)
with refractory ascites. Forty-six patients were in
Child’s class B an 11 in class C. This procedure
was very effective in controlling ascites in all
patients but one. Three patients died during
surgery. Hepatic encephalopathy was detected
in 50 percent of the patients after operation. The
survival rate at 1 and 3 years of follow-up were
72 percent and 36 percent, respectively. Orloff
et al. [8] have recently reported the results
obtained with side-to-side portacaval shunt in
patients with refractory ascites. This report
included 34 cirrhotic patients (91 percent alco-
holics) that were submited to portacaval shunts
because of the presence of refractory ascites (68
percent of the patients were in Child’s B class
and 32 percent in class C). The operative
mortality was very low. Only 6 percent of the
patients died during the 30 postoperative days.
The survival rate at 5, 10 and 15 years were 75
percent, 74 percent and 73 percent, respectively.
Hepatic encephalopathy was detected in only 6
percent of the patients.
The results of these two studies are, in part,
contradictory. As indicated by Orloff and his
associates the best results obtained in their series
may be due to a rigorous lifelong follow-up, that
emphazises abstinence from alcohol and dietary
protein restriction. However, in the study of
Franco et al. continued drinking was not related
to a higher incidence of hepatic encephalopathy.
Therefore, this difference in the incidence of
hepatic encephalopathy is not easily under-
standable. The only possibility is that these two
groups of patients had different degrees of
hepatic impairment. Unfortunately, in both
studies liver function was not reported in detail.
The value of bilirubin, prothrombin time and
albumin, not indicated in these studies, is very
important to compare these two series of
patients. In addition, in neither renal function
was measured by BUN or plasma creatinine.
This again is very important to know since, as
indicated, many patients with refractory ascites
also have HRS. Moreover, the criteria used to
indicate portacaval anastomosis was very im-
precise, since no diuretic requirement and diet
of sodium restriction to define refractory ascites
was clearly established. Finally, in these two
studies the time required to include 57 patients
in Franco’s report and 34 patients in the Orloff
study was 14 and 33 years, respectively. This
data clearly indicate that the patients with
refractory ascites who can benefit by portasys-
temic shunt are very uncommon. Nowadays, it
is difficult to ascertain whether this technique is
the best procedure for these patients.
There are other therapeutic measures that
have been used in the treatment of patients with
refractory ascites. Peritoneovenous shunting
(PVS) in ascitic patients induces a sustained
expansion of the circulatory blood volume,
suppresses RAAS, SNS and ADH, improves
renal function and increases responsiveness to
diuretics [1]. Unfortunately, PVS is associated
with a high rate of complications such as shunt
occlusion, that occurs in more than 40 percent of
the patients at one year of follow-up, vena cava
thrombosis and peritoneal fibrosis. At present,
the indication of PVS has been markedly
reduced, because of the re-introduction of
therapeutic paracentesis [1]. In fact, this techni-HPB INTERNATIONAL 203
que, associated with intravenous administration
of albumin, has been widely used in the
management of ascites and in the treatment of
patients with refractory ascites. A controlled
clinical trial was performed to compare ther-
apeutic paracentesis vs PVS [1]. The results
obtained indicate that, although PVS was better
than paracentesis in the long-term control of
ascites, it does not reduce the total time in
hospital during follow-up or increase survival.
In addition, most patients needed to be reoper-
ated upon because of shunt obstruction. At
present, in many centers therapeutic paracent-
esis associated with intravenous albumin infu-
sion is used in the management of patients with
refractory ascites and those considered as
candidates for liver transplantation.
A number of studies have recently been
published investigating the efficacy of transju-
gular intrahepatic portasystemic shunt (TIPS) in
the management of patients with refractory
ascites [9]. TIPS functionally acts as a side-to-
side portacaval shunt. It produces a reduction in
portal pressure and is associated with favorable
effects on renal function with elimination or
decrease of ascites. The main advantage of TIPS
over surgical portasystemic shunts is that this
technique is less aggressive and probably the
operative mortality is lower. However, obstruc-
tion is common and leads to accumulation of
ascites. Other complications observed are the
development of hepatic encephalopathy and
impairment of liver function due to the shunting
of blood from the liver to the systemic circula-
tion. A recent comparative study in a small
series of patients with refractory ascites showed
increase mortality in patients treated with TIPS,
especially in patients with poor liver function,
compared to patients treated with paracentesis
plus albumin [10]. Therefore, larger controlled
clinical trials are required to define the role of
TIPS in the management of cirrhotic patients
with refractory ascites.
A variety of drugs has been used in patients
with refractory ascites and HRS with only minor
or no effects. Recent studies suggest that the
administration of systemic vasoconstrictors,
particularly ornipressin, combined with plasma
expansion with albumin for a prolonged period
of time (up to 15 days) may markedly improve
renal function in patients with HRS [11]. How-
ever, it should be taken into account that this
therapy may be associated with ischemic com-
plications. Moreover, it is not known whether
the improvement of renal function has a favor-
able effect on survival. Therefore, the usefulness
of this therapy should be evaluated in prospec-
tive controlled investigations.
Without doubt the treatment of choice in
patients with refractory ascites in selected
candidates is liver transplantation [12]. How-
ever, a significant proportion of patients die
before transplantation can be performed because
of their extremely short survival rate. Therefore,
liver transplantation should be indicated, when-
ever possible, before the development of refrac-
tory ascites. Patients most likely to develop
refractory ascites are those with marked sodium
and water retention, dilutional hyponatremia
and marked activation of vasoconstrictor sys-
tems.
In conclusion, although the Orloff report is
very interesting and is in favor of portasystemic
shunts in the management of refractory ascites,
there are several aspects that should be taken in
account before considering what the best proce-
dure for these patients is. The most important
concerns of this report are the following: 1)
There is no a clear definition of refractory
ascites, 2) There is no data on renal and liver
function before the indication of the operation,
3) There is no data on liver histology before
surgery to permit assessment whether these
patients had underlying hepatic cirrhosis, asso-
ciated or not, with alcoholic hepatitis and finally,
4) The number of patients in whom portacaval
shunts was indicated was so small (1 patient per
year) that this therapy should be considered as
anecdotal and only useful in very selective
patients.204 HPB INTERNATIONAL
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Does Sphincteroplasty Predispose to Bile Duct Cancer?
ABSTRACT
Hakamada, K., Sasaki, M., Endoh, M., Itoh, T., Morita, T.
and Konn, M. (1998) Late development of bile duct cancer
after sphincteroplasty: A ten- to twenty-two-year follow-up
study. Surgery; 121, 488-492.
Background: Transduodenal sphincteroplasty is de-
signed to destroy the sphincteric muscle fibers,
producing a terminal choledochoduodenostomy. In
the absence of Oddi’s sphincter, intestinal contents
with both activated pancreatic juice and bacterial
flora are refluxed into the bile duct and remain
there for a prolonged time. The long-term effect
of producing the reflux has not been evaluated to
date.
Methods: One hundred nineteen consecutive pa-
tients undergoing transduodenal sphincteroplasty
between February 1973 and July 1984 were included
in this study. Postoperative clinical courses of 108
patients could be evaluated by means of a retro-
spective review of the hospital records. Median
follow-up was 18 years.
Results: Eight cases (7.4%) of primary bile duct
cancer were found among the 108 cases at intervals
of 1 to 20 years after sphincteroplasty. Two patients
has concurrent hepatolithiasis. The patency of
sphincteroplasty was confirmed in all cases, and
the bile was infected in seven cases. Pathologic
specimens obtained demonstrated cholangiocarcino-
mas and various degrees of atypical hyperplastic
lesions under the background of chronic cholangitis.
Conclusions: Chronic cholangitis can be an impor-
tant causative factor in late development of bile duct
cancer after sphincteroplasty. Any patients treated
with choledochoduodenostomy should be closely
monitored for late cholangiocarcinoma. (Surgery,
1997; 121: 488-492).